CHU Xavier Bichat, 46 rue Henri Huchard, 75877 Paris Cedex 18, France.
Hypertension. 2013 Oct;62(4):794-801. doi: 10.1161/HYPERTENSIONAHA.113.01379. Epub 2013 Aug 5.
Hypertension is a cardiovascular disorder that appears in more than half of the patients with Williams-Beuren syndrome, hemizygous for the elastin gene among 26 to 28 other genes. It was shown that the antihypertensive drug minoxidil, an ATP-dependent potassium channel opener, enhances elastic fiber formation; however, no wide clinical application was developed because of its adverse side effects. The Brown Norway rat was used here as an arterial elastin-deficient model. We tested 3 different potassium channel openers, minoxidil, diazoxide, and pinacidil, and 1 potassium channel blocker, glibenclamide, on cultured smooth muscle cells from Brown Norway rat aorta. All tested potassium channel openers increased mRNAs encoding proteins and enzymes involved in elastic fiber formation, whereas glibenclamide had the opposite effect. The higher steady-state level of tropoelastin mRNA in minoxidil-treated cells was attributable to an increase in both transcription and mRNA stability. Treatment of Brown Norway rats for 10 weeks with minoxidil or diazoxide increased elastic fiber content and decreased cell number in the aortic media, without changing collagen content. The minoxidil-induced cardiac hypertrophy was reduced when animals simultaneously received irbesartan, an angiotensin II-receptor antagonist. This side effect of minoxidil was not observed in diazoxide-treated animals. In conclusion, diazoxide, causing less undesirable side effects than minoxidil, or coadministration of minoxidil and irbesartan, increases elastic fiber content, decreases cell number in the aorta and, thus, could be suitable for treating vascular pathologies characterized by diminished arterial elastin content and simultaneous hypertension.
高血压是一种心血管疾病,在超过一半的患有威廉姆斯-比伦综合征的患者中出现,这些患者的弹性蛋白基因发生了单倍体缺失,同时还存在另外 26 到 28 个基因的缺失。研究表明,降压药米诺地尔,一种 ATP 依赖性钾通道开放剂,可增强弹性纤维的形成;然而,由于其不良反应,并未得到广泛的临床应用。在这里,我们使用布朗-挪威大鼠作为动脉弹性蛋白缺乏模型。我们测试了 3 种不同的钾通道开放剂,米诺地尔、二氮嗪和吡那地尔,以及 1 种钾通道阻滞剂格列本脲,对来自布朗-挪威大鼠主动脉的培养平滑肌细胞进行了测试。所有测试的钾通道开放剂均增加了编码参与弹性纤维形成的蛋白质和酶的 mRNAs,而格列本脲则产生相反的效果。米诺地尔处理的细胞中,原弹性蛋白 mRNA 的稳态水平升高归因于转录和 mRNA 稳定性的双重增加。用米诺地尔或二氮嗪治疗布朗-挪威大鼠 10 周,可增加主动脉中层的弹性纤维含量,减少细胞数量,而不改变胶原含量。当动物同时接受血管紧张素 II 受体拮抗剂厄贝沙坦治疗时,米诺地尔诱导的心脏肥大减少。在接受二氮嗪治疗的动物中没有观察到米诺地尔的这种副作用。总之,二氮嗪引起的不良反应比米诺地尔少,或者米诺地尔和厄贝沙坦联合使用,可增加弹性纤维含量,减少主动脉中的细胞数量,因此可能适合治疗以动脉弹性蛋白含量降低和同时伴有高血压为特征的血管病变。